Compare ADMA Biologics Inc (ADMA) vs Gap Inc (GAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Gap Inc — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Gap Inc trades at $18.36 (market cap $6.86B). The key difference: Gap Inc is far larger — about 3.2× ADMA Biologics Inc's market cap, and Gap Inc pays a 3.67% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GAP | |
|---|---|---|
Market Cap | $2.13B | $6.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $29.13 |
52-Week Low | $7.60 | $18.68 |
Enterprise Value | $2.20B | $9.95B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Gap trades at $19.07, down 0.94% on the day, with a bearish technical signal despite oversold RSI readings. The stock shows strong fundamentals with a P/E of 7.69, net income margin of 6.25%, and robust cash flow. Recent news highlights a turnaround in progress, with nine consecutive positive comps and AI-driven marketing initiatives, though legal investigations and Athleta's rebuild create headwinds.
The outlook is mixed: valuation metrics suggest undervaluation with a consensus price target of $27, but technical weakness and legal risks temper near-term optimism. Earnings growth and digital transformation are key catalysts, while investor sentiment remains cautious amid ongoing legal scrutiny and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
